



Review

Cytotoxic CD4⁺ T-cells during HIV infection: Targets or weapons?

Alexandra Sanchez-Martinez^a, Federico Perdomo-Celis^a, Liliana Acevedo-Saenz^{a,b},
Maria T. Rugeles^a, Paula A. Velilla^{a,*}

^a Grupo Immunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

^b Grupo de Investigación Enfermería-CES, Facultad de Enfermería, Universidad CES, Medellín, Colombia



ARTICLE INFO

Keywords:

CD4
Cytotoxic
CD107a
Granzyme B
Perforin
HIV

ABSTRACT

Classically, CD4⁺ T-cells have been referred as cytokine-producing cells and important players in immune responses by providing soluble factors that potentiate several effector immune functions. However, it is now evident that CD4⁺ T-cells can also elaborate cytotoxic responses, inducing apoptosis of target cells. Cytotoxic CD4⁺ T cells (CD4⁺ CTLs), exhibit cytolytic functions that resemble those of CD8⁺ T-cells; in fact, there is evidence suggesting that they may have a role in the control of viral infections. In this article, we discuss the role of CD4⁺ CTLs during HIV infection, where CD4⁺ CTLs have been associated with viral control and slow disease progression. In addition, we address the implication of CD4⁺ CTLs in the context of antiretroviral therapy and the partial reconstitution of CD8⁺ T-cells effector function.

1. Introduction

CD4⁺ T-cells are critical components of immunity, and by producing various cytokines and expressing co-stimulatory ligands, they contribute to innate immune responses, potentiate CD8⁺ T-cell effector functions, and promote B-cell antibody production. CD4⁺ T-cells also limit exacerbated immune responses through various immunoregulatory mechanisms [1]. Nonetheless, it has been observed that CD4⁺ T-cells may have direct antiviral effector functions through the lysis of infected cells [2]. Indeed, it has been proposed that cytotoxic CD4⁺ T-cells (CD4⁺ CTLs) constitute a unique CD4⁺ T-cell profile, which is generated *via* the interaction of human leukocyte antigen class II (HLA-II)/peptide with T-cell receptor (TCR) in the presence of specific polarizing factors [3]. Importantly, a protective role of CD4⁺ CTLs has also been suggested in infections caused by several viruses such as Epstein-Barr virus [4], dengue virus [5], and influenza virus [6]. However, they may also have a pathogenic role in viral hepatitis [7]. In addition, the antitumor activities of CD4⁺ CTLs have been demonstrated [8,9]. Therefore, CD4⁺ CTLs responses may be relevant in cases of dysfunction or immune evasion of other cytotoxic cells, such as CD8⁺ T-cells and natural killer (NK) cells, or in tissues with regulated cell traffic, such as lymphoid follicles, which exhibit low levels of cytotoxic cells because of low expression of the follicle homing receptor CXCR5 [10].

Antigen-specific CD4⁺ CTLs have been detected in patients with HIV infection [11–15]. Moreover, despite the high degree to which

CD4⁺ T-cells are compromised in HIV infection [16], this cell population may have antiviral activities in some scenarios. For a detailed discussion on the origin, phenotypes, and effector functions of CD4⁺ CTLs and their roles in antiviral immunity, readers are referred to few published papers [2,3,17–19]. In the present review, we discuss the mechanisms underlying CD4⁺ CTL induction during HIV infection and the phenotypes, effector mechanisms, and roles in disease progression. We focus on patients treated for HIV infection, in whom CD4⁺ T-cells can be reconstituted following viral suppression induced by antiretroviral therapy (ART).

2. Origins and phenotypes of CD4⁺ CTLs in HIV infection

To develop into effector subsets, naive CD4⁺ T-cells receive activating signals from professional antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B-cells. These signals are delivered *via* HLA-II/peptide/TCR interactions and are accompanied by secondary co-stimulatory signals, such as CD80/CD86 binding to CD28. The third signal is mediated by local cytokines and is primarily responsible for polarization to a specific CD4⁺ T-cell effector profile [20]. This effector specificity requires a differentiation program that directs CD4⁺ T-cells toward a particular cytotoxic profile. Similar to other CD4⁺ T-cell populations, such as Th1, Th2, and Th17 cells, CD4⁺ CTLs receive specific yet undefined, cytokine signals to express transcriptional and effector profiles that sustain lytic activity [2]. Type-I interferons (IFN) and interleukin (IL)-2 may provide the third signal

* Corresponding author.

E-mail address: paula.velilla@udea.edu.co (P.A. Velilla).

<https://doi.org/10.1016/j.jcv.2019.08.004>

Received 2 April 2019; Received in revised form 16 July 2019; Accepted 13 August 2019

1386-6532/ © 2019 Elsevier B.V. All rights reserved.




Fig. 1. Model of differentiation of CD4⁺ CTLs. Priming of naïve CD4⁺ T-cells by an APC in the presence of IL-2 and type I IFN promote the polarization of CD4⁺ CTLs. Moreover, CD4⁺ CTLs can originate from Th1 and Th17 subsets, most likely in response to IL-2. Finally, in inflammatory conditions, such as HIV infection, memory CD4⁺ T-cells express cytotoxic molecules through the action of common γ -chain cytokines IL-2, IL-7 and IL-15, TNF- α and IL-6, or TLR-2 and 8 ligands.

required for CD4⁺ CTL polarization (Fig. 1). In mouse CD4⁺ T cells, these cytokines induce cooperative action of the transcription factors B lymphocyte-induced maturation protein-1 (Blimp-1) and T-bet via the signal transducer and activator of transcription (STAT) 2 for upregulating the cytotoxic molecules granzyme B and perforin [21]. The transcription factor eomesodermin (Eomes) is also an important regulator of CD4⁺ CTL effector functions [22,23]. CD4⁺ T-cells expressing class I-restricted T-cell-associated molecule (CRTAM) preferentially acquire cytotoxic profiles following activation, because this surface receptor promotes the expression of Eomes, granzyme B, and perforin [24]. Moreover, considering the plasticity of CD4⁺ T-cell responses [25], memory Th1, Th17, or other cell subsets could eventually reprogram their transcriptional profiles in favor of cytotoxic potential (Fig. 1). Accordingly, co-stimulation of antigen-specific Th1 cells with OX40 and 4-1BB by APCs in the presence of IL-2 promotes the acquisition of T-bet, Eomes, and cytotoxic activities [22]. In the presence of IL-2, Th1 and Th17 cells also reportedly co-express granzyme B with IFN- γ and IL-17, respectively [26]. In addition, common γ -chain (IL-2, IL-7, IL-15) and pro-inflammatory (TNF- α and IL-6) cytokines, along with Toll-like receptor (TLR)-2 and TLR-8 ligands, can promote granzyme B release and viral replication in HIV-infected memory CD4⁺ T-cells [26] (Fig. 1). These observations indicate that under the inflammatory conditions of HIV infection, activated memory CD4⁺ T-cells exhibit cytotoxic potential, despite active HIV replication.

HLA-II expression is restricted to professional APCs under steady-state conditions, and compromise of these cells by disease may further limit the production of CD4⁺ CTLs. Yet, at least three sources of antigen presentation have been associated with HIV infection. First, HIV-infected dendritic cells or macrophages, or APCs that have phagocytosed other infected cells, can process and present antigens to naïve CD4⁺ T-cells or antigen-specific CD4⁺ CTLs in a HLA-II-dependent manner

[27,28]. Second, non-APCs can upregulate HLA-II molecules following pathogen challenge or cytokine stimulation. For instance, in the presence of inflammatory conditions or after stimulation with IFN- γ , intestinal epithelial cells upregulate HLA-II molecules [29–31] and may be targets of CD4⁺ CTLs. Third, activated CD4⁺ T cells can bind HIV gp120 via surface receptors, and after processing can present identifying peptides to other antigen-specific CD4⁺ T-cells [32]. Other examples of T–T interactions have been reported [33–35], and these may also play important roles in the induction of CD4⁺ CTL responses to HIV infection of CD4⁺ T cells. Finally, it should be noted that CD4⁺ CTLs are non-specifically cytotoxic following recognition of envelope protein-expressing target cells [11]. These observations are relevant to scenarios of active viral replication and high antigen burden, and partly explain the CD4⁺ CTL responses elicited by a HIV envelope gp160 vaccine in immunized volunteers [36–38].

HLA-II-restricted HIV-specific CD4⁺ CTLs were first detected 30 years ago in cerebrospinal fluids from patients with acquired immunodeficiency syndrome [39]. In later studies, vaccination of seronegative volunteers with an HIV Env protein vaccine elicited CD4⁺ T-cell responses with HLA-II regulated lytic activity [36–38]. Other reports also show recognition of Gag, Env and/or Pol peptides by CD4⁺ T-cells and *in vitro* lysis of peptide-pulsed or HIV-infected target cells [11,40,41]. The first *ex vivo* study of CD4⁺ CTLs in patients with HIV infection was performed by Appay et al, who showed the presence of an important proportion of perforin-expressing CD4⁺ T cells. These had a CD27⁺ CD28⁺ CCR7⁺ CD45RA⁺ CD45RO⁺ CD11a⁺ CD11b⁺ phenotype [12], that is related to late stages of differentiation [42]. Interestingly, perforin⁺ CD4⁺ T-cell numbers were increased in HIV seroconverted patients compared with seronegative controls, and these cells exhibited an activated phenotype (CD38 and Ki-67 expression); the number of these cells were further augmented during chronic infection [12]. Consistent with the fully differentiated stage, perforin-expressing CD28⁺ CD4⁺ T-cells had reduced proliferative capacity, and this was related to clonal expansion during the early stages of HIV infection [12]. Additionally, an expanded subset of p24-specific CD45RO⁺ CCR7⁺ CCR5⁺ CD4⁺ T-cells with lytic capacity was found in peripheral blood from a long-term non-progressive patient [14]. This cell subset also expressed NK cell markers such as CD161 and CD244, but the absence of the TCR V α 24, characteristic of NKT-cells [14]. CCR5 expression, and the activated state indicated by high expression of CD38 was associated with high susceptibility of the CD4⁺ CTL subset to HIV infection [26,43], thus limiting antiviral potential. Recently, Johnson et al. evaluated transcription and phenotype profiles of CD4⁺ CTLs in patients with HIV infection [15], and these data were consistent with previous reports showing a fully mature profile and expression of NK cell markers [12,14]. Specifically, the CD4⁺ CTLs in these studies were characterized by a CD57⁺ KLRG1⁺ CD161⁺ IL-7R⁺ phenotype and expression of T-bet and Eomes, similar to that observed in CD8⁺ T-cells [15]. Studies in Simian Immunodeficiency virus (SIV)-infected macaques have also demonstrated a CD45RA⁺ CD28⁺ CD95⁺ CCR7⁺ phenotype in CD4⁺ CTLs [44]. Phenotypes of CD4⁺ CTLs in patients with HIV infection are listed in Table 1. Collectively, these data indicate that memory CD4⁺ CTLs are generated early during HIV infection after APC priming and differentiation from other CD4⁺ T-cell effector subsets (Fig. 1). Due to activation and expression of the HIV co-receptor CCR5, CD4⁺ CTLs are susceptible to HIV infection and are likely depleted rapidly. Yet a fraction of CD4⁺ CTLs is clonally expanded and acquires a fully differentiated quiescent profile with low proliferative capacity. This profile is maintained throughout chronic infection.

3. Effector mechanisms of CD4⁺ CTLs during HIV infection

Similar to CD8⁺ T-cells, CD4⁺ CTLs mediate cytolytic activities through granule-dependent and independent mechanisms [2] (Table 1 and Fig. 2). An early study of the lytic capacity of CD4⁺ T-cells from patients with HIV infection showed induction of target cell death

Table 1
CD4⁺ CTLs features during HIV infection.

Phenotype	Effector mechanism	Recognized HIV proteins	Role in disease progression	References
N/A	Non-granule-dependent cytotoxicity	Env, Gag	N/A	[11,47]
N/A	Perforin-mediated cytotoxicity; IFN- γ , TNF- α and β -chemokines secretion.	Gag (p24)	N/A	[41,47,52]
CD45RO ⁺ CD11a ⁺ CCR7 ⁻	Perforin-mediated cytotoxicity; IFN- γ and TNF- α secretion.	N/A	N/A	[12]
CD45RO ⁺ CCR7 ⁻ CCR5 ⁺ CD161 ⁺ CD244 ⁺	Granzyme B/Perforin-mediated cytotoxicity; IFN- γ secretion.	Gag	N/A	[14,26,43]
N/A	Degranulation (CD107a expression); IL-2, and IFN- γ secretion.	Gag	No differences between progressor and non-progressors in CD107a ⁺ CD4 ⁺ T-cells	[50]
CD57 ⁺ KLRG1 ⁺ IL-7R ⁻	Degranulation (CD107a expression); Granzyme B/Perforin-mediated cytotoxicity; IFN- γ secretion.	Gag	Higher HIV-specific CD4 ⁺ CTLs in elite controllers and in patients with lower viral set point.	[15,48]

N/A: Not assessed; KLRG1: killer-cell lectin like receptor G1; IFN: Interferon.




Fig. 2. Two scenarios of CD4⁺ CTLs anti-HIV control. CD4⁺ CTLs are characterized by the expression of CD57, KLRG1, CRTAM, T-bet and Eomes. They also exhibit granule-dependent (release of cytotoxic molecules) and independent (FASL) cytotoxic mechanisms and can secrete IFN- γ , TNF- α and β -chemokines. The first scenario of an antiviral role of CD4⁺ CTLs during HIV infection is in the case of HIV-infected macrophages or dendritic cells (1), which can present endocytic or cytosolic antigens in an HLA-II-restricted manner. A second scenario is in the setting of a poor CD8⁺ T-cells response (2), such as in the presence of HIV escape mutations, immune evasion, and exhaustion, evidenced by the expression of the inhibitory receptor programmed death (PD)-1.

through calcium-independent mechanisms, and independently of the release of lytic granules [11]. FAS ligand or TNF-related apoptosis-inducing ligand (TRAIL) may underlie these effector mechanisms [45,46]. Other reports demonstrated granule-dependent cytotoxicity by HIV-specific CD4⁺ CTLs, in which cell death was abrogated by the inhibitor of perforin-mediated killing concanamycin and/or by the chelating agent ethylene glycol tetraacetic acid (EGTA) [12,41]. Another report showed that HIV-specific CD4⁺ CTL clones can differentially exert granule-dependent and independent cytotoxicity [47]. Resembling CD8⁺ T-cells and NK cells, CD4⁺ CTLs have been characterized as perforin- or granzyme-expressing cells [12,14,44,48], and the marker of cell degranulation CD107a [49] is also used to identify CD4⁺ CTLs [15,50]. Moreover, transcriptomic analyses showed that, after antigen-specific stimulation, CD107a⁺ CD4⁺ CTLs express lytic granule-effector proteins such as granulysin, granzyme A, H, K and B, and perforin [15].

In addition to direct lytic mechanisms, CD4⁺ CTLs secrete the antiviral cytokines IFN- γ and TNF- α [12,14,26,43], which promote antigen presentation and inflammatory responses [51]. The β -chemokines macrophage inflammatory protein (MIP)-1 α and MIP-1 β [41,47,52] also block HIV binding and entry into target cells [53,54]. Finally, virus-specific CD4⁺ CTLs may upregulate IL-21 after antigen stimulation [15] and could promote humoral responses [44] or boost CD8⁺ T-cells [55] during HIV/SIV infection. A summary of CD4⁺ CTLs effector mechanisms in patients with HIV infection is shown in Table 1.

It is important to note that all of the studies described above were performed using blood-derived CD4⁺ CTLs. Yet in contrast with blood cells, the cytolytic potential of CD4⁺ T-cells was shown to be limited in lymphoid tissues [56], which are major sites of HIV/SIV replication [57]. These differing cytolytic profiles in blood and lymph nodes correspond with differential expression levels of T-bet and Eomes. In blood samples, granzyme B- and perforin-expressing CD4⁺ CTLs preferentially expressed T-bet^{hi} and Eomes⁺, whereas the frequency of this population was low-undetectable in lymph node tissues. This transcriptional profile is reflected by low expression of granzyme B and perforin in lymph node-confined CD4⁺ T-cells, limited upregulation of cytotoxic molecules following HIV peptide stimulation, and delayed granule release. In concordant evaluations of transcriptional and functional signatures, CD107a⁺ CD4⁺ T-cells from blood and lymph nodes formed separate single-cell clusters, and effector molecules,




Fig. 3. Evaluation of the cytotoxic potential in circulating T-cells in HIV-infected patients under ART. **A.** Peripheral blood mononuclear cells from HIV-infected patients receiving ART for more than one year and with suppressed viral load and recovery of CD4⁺ T-cell counts, where stimulated *ex vivo* with a pool of HIV Gag peptides, in the presence of co-stimulatory antibodies anti-CD28 and anti-CD49d. The expression of granzyme B, perforin and CD107a in T-cells (previous gate in singlet CD3⁺ cells) was evaluated by flow cytometry after 12 h of culture. In the upper panels, representative contour plots from unstimulated and stimulated cells are shown. In red and blue, the proportions of CD8⁺ and CD8⁻ T-cells that are positive for each marker are shown, respectively. In the lower panels, the frequencies of granzyme B⁺, perforin⁺ and CD107a⁺ in stimulated T-cells from all the patients included is shown. The background of CD107a in unstimulated cells was subtracted from peptide-stimulated cells. P value of the Wilcoxon test. **B.** Expression of granzyme B and perforin, as well as CD107a in CD4⁺ and CD8⁺ T-cells after stimulation under similar conditions to that described in **A**, in addition to polyclonal stimulation with PMA/Ionomycin. P value of the Wilcoxon test. NS: not statistically significant. **C.** Frequencies of granzyme B⁺ and perforin⁺ CD8⁻ T-cells in seronegative volunteers and HIV-infected patients on ART. The P value of Mann-Whitney test was > 0.05, not statistically significant (NS). **D.** Frequencies of perforin⁺ and CD107a⁺ CD8⁻ T-cells in HIV-infected patients on ART, and untreated patients, the latter classified according to their plasma viral load (< 2000 and ≥ 2000 RNA copies/mL). P value of the Kruskal-Wallis and Dunn's post-hoc tests (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

including IFN- γ , perforin, and β -chemokines, were poorly expressed in lymph node-confined CD107a⁺ CD4⁺ T-cells [56]. Taken together, these CD4⁺ T-cell features confer limited cytolytic potential and immune surveillance capacity in lymph nodes. Similar characteristics have been reported for CD8⁺ T cells [58], but despite the low cytotoxic potential of T-cells, HIV elite controller patients maintain low viral loads in the absence of therapy. Thus, non-cytolytic factors appear to be involved in the control of HIV in lymphoid tissues [56,58].

4. Roles of CD4⁺ CTLs during untreated HIV infection

Antigen-specific CD4⁺ T-cell responses have been associated with HIV control and slow disease progression [59–62]. However, HIV-specific CD4⁺ T-cells are preferentially infected by HIV [63], and high viremia hampers their responses [64]. Thus, because antigen-specific CD4⁺ T cells are the main targets of HIV, their antiviral roles remain controversial. Nonetheless, the roles of CD4⁺ CTLs during HIV infection are supported by considerable evidence. Specifically, i) HIV elite

controller patients exhibit higher frequencies of circulating HIV-specific CD107a⁺ CD4⁺ CTLs [15], ii) patients with high frequencies of circulating CD57⁺ or granzyme A⁺ CD4⁺ CTLs develop lower viral set points [15], iii) CD8⁺ T-cell depletion in SIV or SIV/HIV-infected macaques does not completely eliminate the lysis of peptide-pulsed target cells *in vivo*, suggesting a CD4-mediated cytotoxicity [65]. Although vestigial CD8⁺ T-cells and NK cells cannot be excluded from these observations, these results are also supported by the emergence of virus-specific CD4⁺ CTLs coinciding with viral control post-CD8 depletion [44]. Further confirming the roles of CD4⁺ CTLs during HIV infection, iv) HIV or SIV-specific CD4⁺ CTLs suppressed viral infection of CD4⁺ T-cells [66,67] and macrophages [27,67], and v) both SIV and HIV Gag-specific CD4⁺ CTLs exerted *in vivo* selective pressure, inducing escape mutations during their control [68,69]. In addition to these lines of evidence, the induction of CD4⁺ CTLs by HIV vaccine candidates suggests that this population provides beneficial lytic activities [37,38]. Moreover, vaccine-induced CD107a⁺ CD4⁺ T-cells, but not cytokine-producing CD4⁺ T-cells, are resistant to depletion following SIV

infection in macaques, resulting in lower viral replication [70]. These data suggest that this cell population controls viral loads through lytic mechanisms and by intrinsic virus resistance and should be enhanced by vaccine candidates.

Although antigen-specific CD4⁺ CTLs are a target of HIV, particularly during acute infection, preserved CD4⁺ CTL responses could play antiviral roles in three scenarios. First, CD4⁺ CTLs are likely important for the lysis of infected macrophages and dendritic cells [27,67], because these cells could present a wider diversity of both endocytic and cytosolic antigens in a HLA-II-dependent manner [71]. Targeting of these cell types is hence pertinent because they act as cellular HIV reservoirs [72]. Secondly, CD4⁺ CTLs may cooperate with CD8⁺ T-cells to achieve lysis of infected cells [15], particularly in the context of a poor CD8⁺ T-cell responses, such as those associated with CD8-escape mutations [73], viral evasion, downregulation of HLA-I molecules [74], and/or CD8⁺ T-cell exhaustion [75] (Fig. 2). A third scenario follows ART-induced viral suppression and is discussed below. Thus, although HIV-specific CD4⁺ CTLs are a target of HIV and are depleted early after infection, the remaining cells may contribute to viral control, particularly by targeting macrophages, dendritic cells, and non-APCs that are not readily eliminated by CD8⁺ T cells. Hence, preserved CD4⁺ CTL responses may comprise antiviral mechanisms in HIV non-progressor patients and could be enhanced by vaccine candidates and immunotherapeutic approaches.

5. Proposed role of CD4⁺ CTLs during HIV infection in the presence of ART-induced viral suppression

Typically, HIV replication is suppressed by ART along with increasing CD4⁺ T-cell counts, depending on nadir CD4⁺ T-cell numbers or naive subpopulations at the time of treatment initiation [76–80]. Moreover, patients with HIV infection who recover CD4⁺ T-cell counts are unlikely to experience counts below the threshold for opportunistic infection risk thereafter [81]. Thus, under conditions of ART-induced viral suppression, recovery of CD4⁺ T-cells may facilitate cytolytic functions. Certainly, the lytic activity of CD4⁺ CTLs in this setting would be significant, because some alterations in the CD8⁺ T-cell cytotoxic program, in addition to persistent activation and exhaustion, are evident in patients with HIV infection and are not fully restored by ART-induced viral suppression [82–85], hence limiting antiviral activities.

Circulating CD4⁺ CTLs have been detected in patients with HIV infection receiving ART [12,50]. However, suppression of viral load and antigenemia may promote migration of antigen-specific CD4⁺ CTLs from the blood to lymphoid tissues, as shown with HIV-specific IFN⁺ CD4⁺ T cells [60] and HIV-specific CD8⁺ T-cells [86]. However, our evaluations of cytotoxic phenotypes in different cohorts of HIV-infected individuals suggest that CD107a⁺ CD8[−] T-cells, which frequencies highly coincide with CD107a⁺ CD4⁺ T-cells, are low but detectable after *ex vivo* HIV Gag stimulation of cells from patients receiving ART (Fig. 3A and B). CD8[−] or CD4⁺ T-cells also contain granzyme B and perforin in their lytic granules, but at consistently lower concentrations than in CD8⁺ T-cells (Fig. 3A and B). In addition, expression levels of granzyme B and perforin are similar between patients with HIV infection receiving ART and seronegative individuals, suggesting that the production of cytotoxic molecules by CD4⁺ T cells is intact in these patients (Fig. 3C). Indeed, CD8[−] T-cells from patients receiving ART exhibit higher expression levels of perforin than cells from untreated patients, both with viral load < 2000 or ≥ 2000 RNA copies/mL (Fig. 3D). Finally, consistent with the migration of antigen-specific CD4⁺ CTLs from blood to lymphoid tissues following viral suppression, patients receiving ART exhibit lower frequencies of Gag-specific CD107a⁺ CD8[−] T-cells than untreated patients (Fig. 3D). Thus, although more studies are required to explore the roles of CD4⁺ CTLs in patients with HIV infection who receive ART, these data support the cytotoxic potential of CD4⁺ T cells.

6. Conclusions

Beyond help, CD4⁺ T-cells can exert direct cytolytic functions and cooperate with other cytotoxic cell populations to control HIV infection. Yet, considering differences in CD4⁺ T-cell profiles between blood and lymphoid tissues, the phenotypic, transcriptional, and functional signatures of CD4⁺ CTLs could be better defined to elucidate their roles in the control of HIV infections. Moreover, considering that most patients with HIV infection receive ART, future studies should focus on this patient group. Such investigations will likely contribute to the understanding of protective T-cell cytolytic functions. Given that lymphoid tissues are sites of augmented HIV replication and act as viral reservoirs, and that lymphoid tissue T-cells are characterized by a lower granule-dependent cytotoxic potential, as indicated by their transcriptional profiles, these studies may distinguish between granule-independent or non-cytolytic mechanisms in terms of the control of viral replication, transcriptional and epigenetic regulation, and their relative efficacy as targets for immunotherapeutic strategies.

Ethical approval

Ethical Approval was provided by IRB of Sede de Investigacion Universitaria, Universidad de Antioquia (certificates 15-08-634 and 11-08-352).

CRediT authorship contribution statement

Alexandra Sanchez-Martinez: Data curation, Writing - original draft, Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing - review & editing. **Federico Perdomo-Celis:** Data curation, Writing - original draft, Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing - review & editing. **Liliana Acevedo-Saenz:** Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing - review & editing. **Maria T. Rugeles:** Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing - review & editing, Funding acquisition, Project administration. **Paula A. Velilla:** Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing - review & editing, Funding acquisition, Project administration.

Declaration of Competing Interest

None declared.

Acknowledgments

Funding: The authors thank CODI (Code: 2562) of the Universidad de Antioquia, and COLCIENCIAS (Code: 111577757038) for their financial support.

References

- [1] S.L. Swain, K.K. McKinstry, T.M. Strutt, Expanding roles for CD4⁺ T cells in immunity to viruses, *Nat. Rev. Immunol.* (2012), <https://doi.org/10.1038/nri3152>.
- [2] J.A. Juno, D. van Bockel, S.J. Kent, A.D. Kelleher, J.J. Zaunders, C.M.L. Munier, Cytotoxic CD4 T cells: friend or foe during viral infection? *Front. Immunol.* (2017), <https://doi.org/10.3389/fimmu.2017.00019>.
- [3] Y. Tian, A. Sette, D. Weiskopf, Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection, *Front. Immunol.* (2016), <https://doi.org/10.3389/fimmu.2016.00531>.
- [4] R. Omiya, C. Buteau, H. Kobayashi, C.V. Paya, E. Celis, Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope, *J. Immunol.* (2002), <https://doi.org/10.4049/jimmunol.169.4.2172>.
- [5] D. Weiskopf, D.J. Bangs, J. Sidney, R.V. Kolla, A.D. De Silva, A.M. de Silva, S. Crotty, B. Peters, A. Sette, Dengue virus infection elicits highly polarized CX3CR1⁺ cytotoxic CD4⁺ T cells associated with protective immunity, *Proc. Natl. Acad. Sci.* (2015), <https://doi.org/10.1073/pnas.1505956112>.
- [6] K.K. McKinstry, T.M. Strutt, Y. Kuang, D.M. Brown, S. Sell, R.W. Dutton, S.L. Swain, Memory CD4⁺ T cells protect against influenza through multiple synergizing mechanisms, *J. Clin. Invest.* (2012), <https://doi.org/10.1172/JCI63689>.

- [7] N. Aslan, C. Yurdaydin, J. Wiegand, T. Greden, A. Ciner, M.F. Meyer, H. Heiken, B. Kuhlmann, T. Kaiser, H. Bozkaya, H.L. Tillmann, A.M. Bozdayi, M.P. Manns, H. Wedemeyer, Cytotoxic CD4+ T cells in viral hepatitis, *J. Viral Hepat.* (2006), <https://doi.org/10.1111/j.1365-2893.2006.00723.x>.
- [8] S.A. Quezada, T.R. Simpson, K.S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P.A. Antony, N.P. Restifo, J.P. Allison, Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts, *J. Exp. Med.* 207 (2010) 637–650, <https://doi.org/10.1084/jem.20091918>.
- [9] Y. Xie, A. Akpınarlı, C. Maris, E.L. Hipkiss, M. Lane, E.-K.M. Kwon, P. Muranski, N.P. Restifo, P.A. Antony, Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma, *J. Exp. Med.* (2010), <https://doi.org/10.1084/jem.20091921>.
- [10] E. Connick, T. Mattila, J.M. Folkvord, R. Schlichtemeier, A.L. Meditz, M.G. Ray, M.D. McCarter, S. MaWhinney, A. Hage, C. White, P.J. Skinner, CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue, *J. Immunol.* (2007), <https://doi.org/10.4049/jimmunol.178.11.6975>.
- [11] M. Heinkelein, I. Euler-König, H. Klinker, H. Ruckle-Lanz, C. Jassoy, Lysis of human immunodeficiency virus type 1 antigen-expressing cells by CD4 and CD8 T cells ex vivo, *J. Infect. Dis.* 174 (1996) 209–213.
- [12] V. Appay, J.J. Zaunders, L. Papagno, J. Sutton, A. Jaramillo, A. Waters, P. Easterbrook, P. Grey, D. Smith, A.J. McMichael, D.A. Cooper, S.L. Rowland-Jones, A.D. Kelleher, Characterization of CD4+ CTLs ex vivo, *J. Immunol.* (2002), <https://doi.org/10.4049/jimmunol.168.11.5954>.
- [13] P.J. Norris, H.F. Moffett, O.O. Yang, D.E. Kaufmann, M.J. Clark, M.M. Addo, E.S. Rosenberg, Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4+ T cells, *J. Virol.* (2004), <https://doi.org/10.1128/JVI.78.16.8844-8851.2004>.
- [14] J.J. Zaunders, W.B. Dyer, B. Wang, M.L. Munier, M. Miranda-Saksena, R. Newton, J. Moore, C.R. Mackay, D.A. Cooper, N.K. Saksena, A.D. Kelleher, Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection, *Blood* (2004), <https://doi.org/10.1182/blood-2003-08-2765>.
- [15] S. Johnson, M. Eller, J.E. Teigler, S.M. Malovec, B.T. Schultz, D.Z. Soghoian, R. Lu, A.F. Oster, A.-L. Chenine, G. Alter, U. Dittmer, M. Marovich, M.L. Robb, N.L. Michael, D. Bolton, H. Streeck, Cooperativity of HIV-specific Cytolytic CD4 T Cells and CD8 T cells in control of HIV Viremia, *J. Virol.* (2015), <https://doi.org/10.1162/neco.2007.3179>.
- [16] K.V. Vijayan, K.P. Karthigeyan, S.P. Tripathi, L.E. Hanna, Pathophysiology of CD4+ T-cell depletion in HIV-1 and HIV-2 infections, *Front. Immunol.* (2017), <https://doi.org/10.3389/fimmu.2017.00580>.
- [17] P.J. van de Berg, E.M. van Leeuwen, I.J. ten Berge, R. van Lier, Cytotoxic human CD4+ T cells, *Curr. Opin. Immunol.* (2008), <https://doi.org/10.1016/j.coi.2008.03.007>.
- [18] D.Z. Soghoian, H. Streeck, Cytolytic CD4+ T cells in viral immunity, *Expert Rev. Vaccines* (2010), <https://doi.org/10.1586/erv.10.132>.
- [19] A. Takeuchi, T. Saito, CD4 CTL, A Cytotoxic subset of CD4(+) T cells, their differentiation and function, *Front. Immunol.* 8 (2017) 194, <https://doi.org/10.3389/fimmu.2017.00194>.
- [20] J. Zhu, H. Yamane, W.E. Paul, Differentiation of effector CD4 T cell populations (*), *Annu. Rev. Immunol.* 28 (2010) 445–489, <https://doi.org/10.1146/annurev-immunol-030409-101212>.
- [21] L. Hua, S. Yao, D. Pham, L.L. Jiang, J. Wright, D. Sawant, A.L. Dent, T.J. Braciale, M.H. Kaplan, J. Sun, Cytokine-dependent induction of CD4+ T cells with cytotoxic potential during influenza virus infection, *J. Virol.* (2013), <https://doi.org/10.1128/JVI.01461-13>.
- [22] H.Z. Qui, A. Menoret, S.L. Reiner, R.S. Mittler, A.J. Adler, A.T. Hagymasi, S. Bandyopadhyay, S.M. Gordon, M.-C. St. Rose, A.T. Vella, R. Ramanarasimhaiah, CD134 plus CD137 dual costimulation induces eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation, *J. Immunol.* (2011), <https://doi.org/10.4049/jimmunol.1101244>.
- [23] K. Eshima, S. Chiba, H. Suzuki, K. Kokubo, H. Kobayashi, M. Iizuka, K. Iwabuchi, N. Shinohara, Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways, *Immunol. Lett.* 144 (2012) 7–15, <https://doi.org/10.1016/j.imlet.2012.02.013>.
- [24] A. Takeuchi, M.E.S.G. Badr, K. Miyauchi, C. Ishihara, R. Onishi, Z. Guo, Y. Sasaki, H. Ike, A. Takumi, N.M. Tsuji, Y. Murakami, T. Katakai, M. Kubo, T. Saito, CRTAM determines the CD4^{sup} & &sup⁺ cytotoxic T lymphocyte lineage, *J. Exp. Med.* 213 (2016) 123 LP–138 LP, <https://doi.org/10.1084/jem.20150519>.
- [25] M. Dupage, J.A. Bluestone, Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease, *Nat. Rev. Immunol.* (2016), <https://doi.org/10.1038/nri.2015.18>.
- [26] J. Couturier, A.T. Hutchison, M.A. Medina, C. Gingaras, P. Urvil, X. Yu, C. Nguyen, P. Mahale, L. Lin, C.A. Kozinetz, J.E. Schmitz, J.T. Kimata, T.C. Savidge, D.E. Lewis, HIV replication in conjunction with granzyme B production by CCR5+ memory CD4 T cells: implications for bystander cell and tissue pathologies, *Virology* (2014), <https://doi.org/10.1016/j.virol.2014.06.008>.
- [27] J.B. Sacha, J.P. Giraldo-Vela, M.B. Buechler, M. a Martins, N.J. Maness, C. Chung, L.T. Wallace, E.J. Leon, T.C. Friedrich, N. a Wilson, A. Hiraoka, D.I. Watkins, Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection, *Proc. Natl. Acad. Sci.* (2009), <https://doi.org/10.1073/pnas.0813106106>.
- [28] R. Wahid, M.J. Cannon, M. Chow, Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio, *J. Virol.* (2005), <https://doi.org/10.1128/JVI.79.10.5988-5995.2005>.
- [29] S. Fais, L. Maiuri, F. Pallone, M. De Vincenzi, G. De Ritis, R. Troncone, S. Auricchio, Gliadin induced changes in the expression of MHC-class II antigens by human small intestinal epithelium. Organ culture studies with coeliac disease mucosa, *Gut*. (1992), <https://doi.org/10.1136/gut.33.4.472>.
- [30] L. Mayer, D. Eisenhardt, P. Salomon, W. Bauer, R. Plous, L. Piccinini, Expression of Class II molecules on intestinal epithelial cells in humans differences between normal and inflammatory bowel disease, *Gastroenterology* (1991), <https://doi.org/10.5555/URI:PII:0016508591905756>.
- [31] S.P. Colgan, M.B. Resnick, C.A. Parkos, C. Delp-Archer, D. McGuirk, A.E. Bacarra, P.F. Weller, J.L. Madara, IL-4 directly modulates function of a model human intestinal epithelium, *J. Immunol.* (1994).
- [32] A. Lanzavecchia, E. Roosnek, T. Gregory, P. Berman, S. Abrignani, T cells can present antigens such as HIV gp120 targeted to their own surface molecules, *Nature* (1988), <https://doi.org/10.1038/334530a0>.
- [33] C.R. Hewitt, M. Feldmann, Human T cell clones present antigen, *J. Immunol.* 143 (1989) 762–769.
- [34] T. Wyss-Coray, C. Brander, F. Bettens, D. Mijic, W.J. Pichler, Use of antibody/peptide constructs of direct antigenic peptides to T cells: evidence for T cell processing and presentation, *Cell. Immunol.* 139 (1992) 268–273.
- [35] V. Barnaba, C. Watts, M. de Boer, P. Lane, A. Lanzavecchia, Professional presentation of antigen by activated human T cells, *Eur. J. Immunol.* (1994), <https://doi.org/10.1002/eji.1830240112>.
- [36] R.J. Orentas, J.E.K. Hildreth, E. Obah, M. Polydefkis, G.E. Smith, M. Lou Clements, R.F. Siliciano, Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine, *Science* (80-) (1990), <https://doi.org/10.1126/science.2190315>.
- [37] P.E. Stanhope, A.Y. Liu, W. Pavlat, P.M. Pitha, M.L. Clements, R.F. Siliciano, An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes, *J. Immunol.* 150 (1993) 4672–4686.
- [38] P.E. Stanhope, M.L. Clements, R.F. Siliciano, Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine, *J. Infect. Dis.* 168 (1993) 92–100.
- [39] H.S.I. Sethi, K.K. Naher, © 1988 Nature Publishing Group, *Nature* 335 (1988) 178181, <https://doi.org/10.1038/332141a0>.
- [40] S.K. Kundu, T.C. Merigan, Equivalent recognition of HIV proteins, Env, gag and pol, by CD4+ and CD8+ cytotoxic T-lymphocytes, *AIDS* (1992), <https://doi.org/10.1097/00002030-199209000-00031>.
- [41] P.J. Norris, M. Sumaroka, C. Brander, H.F. Moffett, S.L. Boswell, T. Nguyen, Y. Sykulev, B.D. Walker, E.S. Rosenberg, Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones, *J. Virol.* 75 (2001) 9771–9779, <https://doi.org/10.1128/JVI.75.20.9771-9779.2001>.
- [42] V. Appay, The physiological role of cytotoxic CD4(+) T-cells: the holy grail? *Clin. Exp. Immunol.* 138 (2004) 10–13, <https://doi.org/10.1111/j.1365-2249.2004.02605.x>.
- [43] J.J. Zaunders, M.L. Munier, D.E. Kaufmann, S. Ip, P. Grey, D. Smith, T. Ramacciotti, D. Quan, R. Finlayson, J. Kaldor, E.S. Rosenberg, B.D. Walker, D.A. Cooper, A.D. Kelleher, Early proliferation of CCR5+ CD38+ CD4+ Th1 effector cells during primary HTV-1 infection, *Blood* (2005), <https://doi.org/10.1182/blood-2005-01-0206>.
- [44] G.N. Pavlakis, C. Alicea, A. von Gegerfelt, D.C. Montefiori, A. Valentin, K.K.A. Van Rompay, M.L. Marthas, B.K. Felber, Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-Depleted macaques infected with rev-independent live-attenuated simian immunodeficiency virus, *J. Immunol.* (2010), <https://doi.org/10.4049/jimmunol.1000572>.
- [45] T. Stalder, S. Hahn, P. Erb, C.V. Paya, E. Celis, Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity, *J. Immunol.* (1994), <https://doi.org/10.4049/jimmunol.169.4.2172>.
- [46] N. Kayagaki, N. Yamaguchi, M. Nakayama, A. Kawasaki, H. Akiba, K. Okumura, H. Yagita, Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity, *J. Immunol.* (1999).
- [47] B. Lotti, T. Wendland, H. Furrer, N. Yawalkar, S. Von Greyerz, K. Schnyder, M. Brandes, P. Vernazza, R. Wagner, T. Nguyen, E. Rosenberg, W.J. Pichler, C. Brander, Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines, *J. Clin. Immunol.* 22 (2002) 253–262, <https://doi.org/10.1023/A:1020066404226>.
- [48] S. Soghoian, Damien Z. Heiko, Jessen Michael Flanders, Sierra-Davidson Sam Kailan, Cutler Thomas, Pertel Srinika, Ranasinghe Madelene, Lindqvist Isaiiah, Davis Kimberly, Lane Jenna, Eric S. Rychert, Abraham L. Rosenberg Alicia Piechicka-Trocha, Brass Jason, HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome, *Sci. Transl. Med.* 29:4 (February 123) (2012) 123ra25, <https://doi.org/10.1146/annurev-cellbio-092910-154240.Sensory Doi10.1126/Scitranslmed.3003165>. (2012).
- [49] M.R. Betts, J.M. Brechley, D.A. Price, S.C. De Rosa, D.C. Douek, M. Roederer, R.A. Koup, Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation, *J. Immunol. Methods* 281 (2003) 65–78.
- [50] E. Nemes, L. Bertoncelli, E. Lugli, M. Pinti, M. Nasi, L. Manzini, S. Manzini, F. Prati, V. Borghi, A. Cossarizza, C. Mussini, Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection, *Aids* 24 (2010) 947–957, <https://doi.org/10.1097/QAD.0b013e328337b144>.
- [51] N. Gulzar, K. Copeland, CD8+ T-Cells: function and response to HIV infection, *Curr. HIV Res.* (2004), <https://doi.org/10.2174/1570162043485077>.
- [52] P.J. Norris, H.F. Moffett, O.O. Yang, E. Daniel, M.J. Clark, M.M. Addo, S. Eric, D.E. Kaufmann, E.S. Rosenberg, Beyond help : direct effector functions of human immunodeficiency virus type 1-specific CD4 g t cells, *J. Virol.* 78 (2004)

- 8844–8851, <https://doi.org/10.1128/JVI.78.16.8844>.
- [53] K.O. Saunders, S. Ward-Caviness, R.J. Schutte, S.A. Freil, R.G. Overman, N.M. Thielman, C.K. Cunningham, T.B. Kepler, G.D. Tomaras, Secretion of MIP-1 β and MIP-1 α by CD8+ T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage, *Cell. Immunol.* (2011), <https://doi.org/10.1016/j.cellimm.2010.09.011>.
- [54] F. Cocchi, A.L. DeVico, A. Garzino-Demo, S.K. Arya, R.C. Gallo, P. Lusso, Identification of RANTES, MIP-1 α , and MIP-1 β as the major HIV-suppressive factors produced by CD8+ T cells, *Science* (80-) (1995), <https://doi.org/10.1126/science.270.5243.1811>.
- [55] L. White, S. Krishnan, N. Strbo, H. Liu, M.A. Kolber, M.G. Lichtenheld, R.N. Pahwa, S. Pahwa, Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degradation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV), *Blood* 109 (2007) 3873–3880, <https://doi.org/10.1182/blood-2006-09-045278>.
- [56] M. Buggert, S. Nguyen, L.M. McLane, M. Steblyanko, N. Anikeeva, D. Paquin-Proulx, P.M. Del Rio Estrada, Y. Ablanedo-Terrazas, K. Noyan, M.A. Reuter, K. Demers, J.K. Sandberg, M.A. Eller, H. Streeck, M. Jansson, P. Nowak, A. Sönnberg, D.H. Canaday, A. Naji, E.J. Wherry, M.L. Robb, S.G. Deeks, G. Reyes-Teran, Y. Sykulev, A.C. Karlsson, M.R. Betts, Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease, *PLoS Pathog.* (2018), <https://doi.org/10.1371/journal.ppat.1006973>.
- [57] J.D. Estes, C. Kityo, F. Ssali, L. Swainson, K.N. Makamdop, G.Q. Del Prete, S.G. Deeks, P.A. Luciw, J.G. Chipman, G.J. Beilman, T. Hoskuldsson, A. Khoruts, J. Anderson, C. Deleage, J. Jasurda, T.E. Schmidt, M. Hafertepe, S.P. Callisto, H. Pearson, T. Reimann, J. Schuster, J. Schoephoerster, P. Southern, K. Perkey, L. Shang, S.W. Wietgreffe, C.V. Fletcher, J.D. Lifson, D.C. Douek, J.M. McCune, A.T. Haase, T.W. Schacker, Defining total-body AIDS-virus burden with implications for curative strategies, *Nat. Med.* (2017), <https://doi.org/10.1038/nm.4411>.
- [58] M.A. Reuter, P.M. Del Rio Estrada, M. Buggert, C. Petrovas, S. Ferrando-Martinez, S. Nguyen, A. Sada Japp, Y. Ablanedo-Terrazas, A. Rivero-Arrieta, L. Kuri-Cervantes, H.M. Gunzelman, E. Gostick, D.A. Price, R.A. Koup, A. Naji, D.H. Canaday, G. Reyes-Teran, M.R. Betts, HIV-specific CD8+ T cells exhibit reduced and differentially regulated cytolytic activity in lymphoid tissue, *Cell Rep.* 21 (2017) 3458–3470, <https://doi.org/10.1016/j.celrep.2017.11.075>.
- [59] E.S. Rosenberg, J.M. Billingsley, A.M. Caliendo, S.L. Boswell, P.E. Sax, S.A. Kalams, B.D. Walker, Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia, *Science* (80-) (1997), <https://doi.org/10.1126/science.278.5342.1447>.
- [60] C.J. Pitcher, C. Quittner, D.M. Peterson, M. Connors, R.A. Koup, V.C. Maino, L.J. Picker, HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression, *Nat. Med.* (1999), <https://doi.org/10.1038/8400>.
- [61] M.F. Chevalier, B. Julg, A. Pyo, M. Flanders, S. Ranasinghe, D.Z. Soghoian, D.S. Kwon, J. Rychert, J. Lian, M.I. Muller, S. Cutler, E. McAndrew, H. Jensen, F. Pereyra, E.S. Rosenberg, M. Altfeld, B.D. Walker, H. Streeck, HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function, *J. Virol.* 85 (2011) 733–741, <https://doi.org/10.1128/JVI.02030-10>.
- [62] M. Schieffer, H.K. Jensen, A.F. Oster, F. Pissani, D.Z. Soghoian, R. Lu, A.B. Jensen, C. Zedlack, B.T. Schultz, I. Davis, S. Ranasinghe, E.S. Rosenberg, G. Alter, R.R. Schumann, H. Streeck, Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control, *J. Virol.* (2014), <https://doi.org/10.1128/JVI.00728-14>.
- [63] D.C. Douek, J.M. Brenchley, M.R. Betts, D.R. Ambrozak, B.J. Hill, Y. Okamoto, J.P. Casazza, J. Kuruppu, K. Kunstman, S. Wolinsky, Z. Grossman, M. Dybul, A. Oxenius, D.A. Price, M. Connors, R.A. Koup, HIV preferentially infects HIV-specific CD4+ T cells, *Nature* (2002), <https://doi.org/10.1038/417095a>.
- [64] A.C. McNeil, W.L. Shupert, C.A. Iyasere, C.W. Hallahan, J.A. Mican, R.T.J. Davey, M. Connors, High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation, *Proc. Natl. Acad. Sci. U. S. A.* 98 (2001) 13878–13883, <https://doi.org/10.1073/pnas.251539598>.
- [65] S. Chea, C.J. Dale, R. De Rose, I.A. Ramshaw, S.J. Kent, Enhanced cellular immunity in macaques following a novel peptide immunotherapy, *J. Virol.* (2005), <https://doi.org/10.1128/JVI.79.6.3748-3757.2005>.
- [66] V.I. Ayala, M.T. Trivett, L.V. Coren, S. Jain, P.S. Bohn, R.W. Wiseman, D.H. O'Connor, C. Ohlen, D.E. Ott, A novel SIV gag-specific CD4+ T-cell clone suppresses SIVmac239 replication in CD4+ T cells revealing the interplay between antiviral effector cells and their infected targets, *Virology* (2016), <https://doi.org/10.1016/j.virol.2016.03.013>.
- [67] N. Zheng, M. Fujiwara, T. Ueno, S. Oka, M. Takiguchi, Strong ability of nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages, *J. Virol.* 83 (2009) 7668–7677, <https://doi.org/10.1128/JVI.00513-09>.
- [68] B.J. Burwitz, J.P. Giraldo-Vela, J. Reed, L.P. Newman, A.T. Bean, F.A. Nimityongskul, P.A. Castrovinski, N.J. Maness, E.J. Leon, R. Rudersdorf, J.B. Sacha, CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller, *Retrovirology* (2012), <https://doi.org/10.1186/1742-4690-9-91>.
- [69] N. Erdmann, V.Y. Du, J. Carlson, M. Schaefer, A. Jureka, S. Sterrett, L. Yue, D. Dilemnia, S. Lakhi, J. Tang, J. Sidney, J. Gilmour, S. Allen, E. Hunter, S. Heath, A. Bansal, P.A. Goepfert, HLA Class-II associated HIV polymorphisms predict escape from CD4+ T cell responses, *PLoS Pathog.* (2015), <https://doi.org/10.1371/journal.ppat.1005111>.
- [70] K. Terahara, H. Ishii, T. Nomura, N. Takahashi, A. Takeda, T. Shiino, Y. Tsunetsugu-Yokota, T. Matano, Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection, *J. Virol.* (2014), <https://doi.org/10.1128/JVI.02032-14>.
- [71] M.K. Tewari, G. Sinnathamby, D. Rajagopal, L.C. Eisenlohr, A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent, *Nat. Immunol.* (2005), <https://doi.org/10.1038/ni1171>.
- [72] J.B. Honeycutt, W.O. Thayer, C.E. Baker, R.M. Ribeiro, S.M. Lada, Y. Cao, R.A. Cleary, M.G. Hudgens, D.D. Richman, J. Victor Garcia, HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy, *Nat. Med.* (2017), <https://doi.org/10.1038/nm.4319>.
- [73] C. Bronke, C.A.M. Almeida, E. McKinnon, S.G. Roberts, N.M. Keane, A. Chopra, J.M. Carlson, D. Heckerman, S. Mallal, M. John, HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes, *AIDS* (2013), <https://doi.org/10.1097/QAD.0b013e32835e1616>.
- [74] K.L. Collins, B.K. Chen, S.A. Kalams, B.D. Walker, D. Baltimore, HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes, *Nature* (1998), <https://doi.org/10.1038/34929>.
- [75] C.L. Day, D.E. Kaufmann, P. Kiepiela, J.A. Brown, E.S. Moodley, S. Reddy, E.W. Mackey, J.D. Miller, A.J. Leslie, C. DePierres, Z. Mncube, J. Duraiswamy, B. Zhu, Q. Eichbaum, M. Altfeld, E.J. Wherry, H.M. Coovadia, P.J.R. Goulder, P. Klennerman, R. Ahmed, G.J. Freeman, B.D. Walker, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression, *Nature* (2006), <https://doi.org/10.1038/nature05115>.
- [76] N.G. Pakker, E.D.M.B. Kroon, M.T.L. Roos, S.A. Otto, D. Hall, F.W.N.M. Wit, D. Hamann, M.E. Van der Ende, F.A.P. Claessen, R.H. Kauffmann, P.P. Koopmans, F.P. Kroon, C.H.H. Ten Napel, H.G. Sprenger, H.M. Weigel, J.S.G. Montaner, J.M.A. Lange, P. Reiss, P.T.A. Schellekens, F. Miedema, Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy, *AIDS* (1999), <https://doi.org/10.1097/00002030-199902040-00008>.
- [77] D.W. Notermans, N.G. Pakker, D. Hamann, N. a Foudraire, R.H. Kauffmann, P.L. Meenhof, J. Goudsmit, M.T. Roos, P.T. Schellekens, F. Miedema, S. a Danner, Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults, *J. Infect. Dis.* (1999), <https://doi.org/10.1093/cid/cit013>.
- [78] J.J. Lok, R.J. Bosch, C.A. Benson, A.C. Collier, G.K. Robbins, R.W. Shafer, M.D. Hughes, Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection, *AIDS* (2010), <https://doi.org/10.1097/QAD.0b013e32833adbef>.
- [79] E. Negrodo, M. Massanella, J. Puig, N. Perez-Alvarez, J.M. Gallego-Escuredo, J. Villarroya, F. Villarroya, J. Molto, J.R. Santos, B. Clotet, J. Blanco, Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications, *Clin. Infect. Dis.* 50 (2010) 1300–1308, <https://doi.org/10.1086/651689>.
- [80] G.K. Robbins, J.G. Spritzler, E.S. Chan, D.M. Asmuth, R.T. Gandhi, B.A. Rodriguez, G. Skowron, P.R. Skolnik, R.W. Shafer, R.B. Pollard, Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS clinical trials group protocol 384, *Clin. Infect. Dis.* (2009), <https://doi.org/10.1086/595888>.
- [81] H.B. Gale, S.R. Gitterman, H.J. Hoffman, F.M. Gordin, D.A. Benator, A.M. Labriola, V.L. Kan, Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts <= 300 cells/ μ L and HIV-1 suppression? *Clin. Infect. Dis.* 56 (2013) 1340–1343, <https://doi.org/10.1093/cid/cit004>.
- [82] F. Perdomo-Celis, P.A. Velilla, N.A. Taborda, M.T. Rugeles, An altered cytotoxic program of CD8+ T-cells in HIV-infected patients despite HAART-induced viral suppression, *PLoS One* 14 (2019) e0210540, <https://doi.org/10.1371/journal.pone.0210540>.
- [83] P.W. Hunt, J.N. Martin, E. Sinclair, B. Bredt, E. Hagos, H. Lampiris, S.G. Deeks, T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy, *J. Infect. Dis.* 187 (2003) 1534–1543, <https://doi.org/10.1086/374786>.
- [84] R.F. Tanko, A.P. Soares, L. Masson, N.J. Garrett, N. Samsunder, Q. Abdool Karim, S.S. Abdool Karim, C. Riou, W.A. Burgers, Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression, *Clin. Immunol.* 195 (2018) 127–138, <https://doi.org/10.1016/j.clim.2018.06.001>.
- [85] L. Trautmann, L. Janbazian, N. Chomont, E.A. Said, S. Gimmig, B. Bessette, M.R. Boulassel, E. Delwart, H. Sepulveda, R.S. Balderas, J.P. Routy, E.K. Haddad, R.P. Sekaly, Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction, *Nat. Med.* (2006), <https://doi.org/10.1038/nm1482>.
- [86] M. Altfeld, J. Van Lunzen, N. Frahm, X.G. Yu, C. Schneider, R.L. Eldridge, M.E. Feeney, D. Meyer-Olson, H.J. Stellbrink, B.D. Walker, Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection, *J. Clin. Invest.* (2002), <https://doi.org/10.1172/JCI0214789>.